Have a personal or library account? Click to login
Diagnostic and Therapeutic Approaches in the Treatment of Gastric Cancer – A Scoping Review Cover

Diagnostic and Therapeutic Approaches in the Treatment of Gastric Cancer – A Scoping Review

Open Access
|Feb 2026

References

  1. Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenter-ol. 2014;20(7):1667-80.
  2. Piazuelo MB, Correa P. Gastric cáncer: Overview. Colomb Med (Cali). 2013;44(3):192-201.
  3. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21(11):4012.
  4. Kim YI, Kim YA, Lee H, et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project. Oncotarget. 2017;9(5):5961-5973.
  5. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
  6. Lin JL, Lin JX, Li P, et al. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health. 2024;24(1):1763.
  7. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457-9.
  8. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648.
  9. Anderson WF, Rabkin CS, Turner N, et al. The changing face of noncardia gastric cancer incidence among US non-hispanic whites. J Natl Cancer Inst. 2018;110(6):608–615.
  10. Camargo MC, Anderson WF, King JB, et al. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011;60(12):1644–1649.
  11. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-49.
  12. Ramachandran R, Grantham T, Singh S et al. Gastric Cancer: Clinical Features, Screening, Diagnosis, Treatment, and Prevention. Cureus. 2024;16(3):e55598.
  13. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Gastric Cancer. [Updated 2024 Apr 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459142/
  14. Prognosis and Treatment of Gastric Cancer: A 2024 Update. J Clin Med. 2024;13(9):2748.
  15. Sun K, Jia K, Lv H et al. EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives. Front Oncol. 2020;10:583463.
  16. Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013;16(6):358-65.
  17. Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187-1203.
  18. Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1998-2001.
  19. Wang Q, Chen Y, Wang X, et al. Consumption of fruit, but not vegetables, may reduce risk of gastric cancer: results from a meta-analysis of cohort studies. Eur J Cancer. 2014;50(8):1498-509.
  20. Ferro A, Costa AR, Morais S, et al. Fruits and vegetables intake and gastric cancer risk: a pooled analysis within the Stomach cancer Pooling Project. Int J Cancer. 2020;147(11):3090-3101.
  21. Piazuelo MB, Correa P. Atrophic gastritis: a state-of-the-art overview. Am J Gastroenterol. 2021;116(6):1126-1140.
  22. Figueiredo J, Melo S, Carneiro P, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet. 2019;56(4):199-208.
  23. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-62.
  24. Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309-18.
  25. van Hootegem SJM, Chmelo J, van der Sluis PC, et al. The yield of diagnostic laparoscopy with peritoneal lavage in gastric adenocarcinoma: a retrospective cohort study. Eur J Surg Oncol. 2024;50(3):108233.
  26. Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2012;15 Suppl 1:S38-47.
  27. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005-1020.
  28. Tibshirani R. The Lasso Method for Variable Selection in the Cox Model. Stat Med. 1997;16(4):385–95.
  29. Wang Q, Liu G, Hu C. Molecular Classification of Gastric Adenocarcinoma. Gastroenterology Res. 2019;12(6):275-282.
  30. Costa M, Fernandes CL, Magalhães H. Perioperative Treatment in Gastric Cancer: A Fast-Changing Field. Cancers (Basel). 2024;16(23):4036.
  31. Yuan SQ, Nie RC, Jin Y, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esopha-geal junction cancer: A randomized phase 2 trial. Nat Med. 2024;30(2):552-559.
  32. Derks S, Liao X, Chiaravalli AM, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. On-cotarget. 2016;7(22):32925-32.
  33. Zhang C, Li D, Yu R, et al. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature. Front Immunol. 2021;12:651033.
  34. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693-706.
  35. Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22(4):466-78.
  36. Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest. 2008;118(5):1727-38.
  37. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91-102.
  38. Yasumoto K, Koizumi K, Kawashima A, et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006;66(4):2181-7.
  39. D‘Angelica M, Gonen M, Brennan MF et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808-16.
  40. van Hootegem SJM, Guchelaar NAD, van der Sluis K, et al. Staging laparoscopy for gastric cancer: European consensus. Br J Surg. 2025;112(9):znaf144.
  41. Wanebo HJ, Kennedy BJ, Chmiel J et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583-92.
  42. Darou-e-Kolaie MK, Hosseini K, Kamali-Sarvestani E. Sister Mary Joseph nodule-A case report with review of literature. J Res Med Sci. 2011;16(1):105-8.
  43. Hamid K, Hamza M, Rezac L, Shrestha A. Linitis Plastica. S D Med. 2022;75(8):375.
  44. Aurello P, Petrucciani N, Antolino L, et al. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Medicine (Baltimore). 2017;96(29):e7578.
  45. American Cancer Society. Stomach (Gastric) Cancer Stages. Available from: https://www.cancer.org/cancer/types/stomach-cancer/detection-diagnosis-staging/staging.html
  46. Kim JH, Jun KH, Jung H, et al. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer. Hepatogastroenterology. 2014;61(132):863-9.
  47. van der Sluis K, Taylor SN, Kodach LL, et al. Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: a nationwide study. Eur J Cancer. 2024;199:113541.
  48. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583-92.
  49. Andre T, Tougeron D, Piessen G, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized DNA Mis-match Repair-Deficient/Microsatellite Instability-High Gastric or Gastroesophageal Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41(2):255-265.
  50. Paraneoplastic Syndromes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507890/
  51. Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology. 1982;82(2):228-31.
  52. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545-1575.
  53. Lim JS, Yun MJ, Kim MJ, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2006;26(1):143-56.
  54. Burbidge S, Mahadya K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013;68(3):251-5.
  55. Akcakaya A, Alimoglu O. The role of laparoscopic staging for the management of gastric cancer. Prz Gastroenterol. 2020;15(4):329-335.
  56. Leake P-A, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2012;15(1):S38-S47.
  57. Yang AP, Liu J, Lei HY, et al. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Clin Chim Acta. 2014;437:183-6.
  58. Jin Y, Wang H, Chen X, et al. Evaluation of the value of combined detection of tumor markers CA724, carcinoembryonic antigen, CA242, and CA19-9 in gastric cancer. Medicine (Baltimore). 2024;103(19):e37989.
  59. Guo J, Chen S, Li S, et al. A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4). Onco-target. 2018;9(6):4814-4822.
  60. Cancer Research UK. Survival for stomach cancer. Available at: https://www.cancerresearchuk.org/about-cancer/stomach-cancer/survival
  61. de Vos tot Nederveen Cappel W, Nagengast FM, Grinjoen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study of 114 families. Dis Colon Rectum. 2002;45(12):1588-94.
  62. Wei T, Wu Z, Chen Y, et al. Comparison of uncut Roux-en-Y anastomosis and Billroth-II with Braun anastomosis after distal gastrectomy. Front Surg. 2024;11:1356502.
  63. Marano L, Braccio B, Schettino M, et al. Sutureless jejuno-jejunal anastomosis in gastric cancer patients: a comparison with handsewn procedure in a single institute. BMC Surg. 2012;12 Suppl 1:S27.
  64. Svendsen LB, Larsen TM. Nutritional consequences of gastrectomy. Ugeskr Laeger. 2012;174(38):2191-4.
  65. Heo YJ, Park JM, Kim SH, et al. Postoperative metabolic and nutritional derangements after total gastrectomy in gastric cancer patients. J Gastric Cancer. 2018;18(3):264-273.
  66. Tey CJ, Poon D, Toh E, et al. Endoscopic palliation and nutritional support in advanced gastric cancer. JGH Open. 2018;3(2):161-167.
  67. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Stomach Cancer. 2023. Available from: https://www.nccn.org/patients/guidelines/content/PDF/stomach-patient.pdf
  68. Pachiadakis I, Tsilimigras DI, Schizas D, Moris D. Palliative management of malignant gastric outlet obstruction: An evidence-based review. World J Gastrointest Endosc. 2020;12(12):503-514.
  69. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastu-zumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
  70. He CZ, Zhang KH, Li Q, et al. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.
  71. Giampieri R, Cantini L, Bittoni A, et al. The role of biologic and targeted therapies in the treatment of elderly patients with advanced gastric cancer. Expert Opin Biol Ther. 2016;16(2):179-91.
DOI: https://doi.org/10.2478/amb-2026-0035 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Language: English
Page range: 232 - 238
Submitted on: Jan 20, 2026
|
Accepted on: Jan 26, 2026
|
Published on: Feb 21, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 K. Angelov, N. Nachev, E. Yordanov, S. Stoyanova, N. Khayat, A. Sharkov, A. Zlatarov, T. Dyulgerov, published by Medical University - Sofia
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.